EGFR and neoplasm: Our working hypothesis predicted that administration of Lapatinib at the beginning of the resting (diurnal) phase to mice carrying EGFR/HER2-driven tumours would better inhibit tumorigenic growth relative to administration during the active phase, in which EGFR signalling is anyhow robustly suppressed by liganded GRs.